Oct-4 is associated with gastric cancer progression and prognosis
To investigate the clinical significance of Oct-4 in the development and progression of gastric cancer. Immunohistochemistry was used to analyze Oct-4 expression in 412 gastric cancer cases. Oct-4 protein levels were upregulated in gastric cancer tissues compared with adjacent noncancerous tissues....
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2016-01, Vol.9, p.517-522 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 522 |
|---|---|
| container_issue | |
| container_start_page | 517 |
| container_title | OncoTargets and therapy |
| container_volume | 9 |
| creator | Jiang, Wen-Li Zhang, Peng-Fei Li, Guo-Feng Dong, Jian-Hua Wang, Xue-Song Wang, Yuan-Yu |
| description | To investigate the clinical significance of Oct-4 in the development and progression of gastric cancer.
Immunohistochemistry was used to analyze Oct-4 expression in 412 gastric cancer cases. Oct-4 protein levels were upregulated in gastric cancer tissues compared with adjacent noncancerous tissues.
Positive expression of Oct-4 correlated with age, depth of invasion, Lauren classification, lymph node metastasis, distant metastasis, and TNM stage. In stages I, II, and III, the 5-year survival rate of patients with high expression of Oct-4 was significantly lower than that in patients with low expression of Oct-4. In stage IV, Oct-4 expression did not correlate with the 5-year survival rate. Furthermore, multivariate analysis suggested that the depth of invasion, lymph node metastasis, distant metastasis, TNM stage, and upregulation of Oct-4 were independent prognostic factors of gastric cancer.
Oct-4 protein is a useful marker in predicting tumor progression and prognosis. |
| doi_str_mv | 10.2147/OTT.S90031 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4734804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A500288913</galeid><sourcerecordid>A500288913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c602t-9ea92728744bf238ef5b32becc4d1beb56b8470dcac62dce7fe61b7d57662acc3</originalsourceid><addsrcrecordid>eNqNkl1rFDEUhoNYbK3e-ANkQBARZs3XJJkbYSlqC4W9cL0OmcyZ3ZTZZE0yiv_e1K3dXSlUcpGv57wn4X0RekXwjBIuPyyWy9nXFmNGnqAzQqSqRcvw04P1KXqe0g3GQijKn6FTKpRoZSvP0Hxhc80rlyqTUrDOZOirny6vq5VJOTpbWeMtxGobwypCSi74yvj-z96H5NILdDKYMcHLu_kcffv8aXlxWV8vvlxdzK9rKzDNdQumpZIqyXk3UKZgaDpGO7CW96SDrhGd4hL31lhBewtyAEE62TdSCGqsZefo4053O3UbKITP0Yx6G93GxF86GKePb7xb61X4oblkXGFeBN7dCcTwfYKU9cYlC-NoPIQpaSJFQ0ijeFPQN_-gN2GKvnxPU8ppK3DD1J5amRG080Mofe2tqJ43mBWsvP0RClOlWsIKNXuAKqOHjbPBw-DK-ZHsfxbsO7w9KFiDGfM6hXHKxdF0rPwIuFd8vwNtDClFGO7NIFjfJlOXZOpdMgv8-tC-e_RvFNlveKDaXA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242960538</pqid></control><display><type>article</type><title>Oct-4 is associated with gastric cancer progression and prognosis</title><source>DOVE Medical Press Journals</source><source>PubMed Central Open Access</source><source>PubMed (Medline)</source><source>Taylor & Francis</source><source>EZB Electronic Journals Library</source><creator>Jiang, Wen-Li ; Zhang, Peng-Fei ; Li, Guo-Feng ; Dong, Jian-Hua ; Wang, Xue-Song ; Wang, Yuan-Yu</creator><creatorcontrib>Jiang, Wen-Li ; Zhang, Peng-Fei ; Li, Guo-Feng ; Dong, Jian-Hua ; Wang, Xue-Song ; Wang, Yuan-Yu</creatorcontrib><description>To investigate the clinical significance of Oct-4 in the development and progression of gastric cancer.
Immunohistochemistry was used to analyze Oct-4 expression in 412 gastric cancer cases. Oct-4 protein levels were upregulated in gastric cancer tissues compared with adjacent noncancerous tissues.
Positive expression of Oct-4 correlated with age, depth of invasion, Lauren classification, lymph node metastasis, distant metastasis, and TNM stage. In stages I, II, and III, the 5-year survival rate of patients with high expression of Oct-4 was significantly lower than that in patients with low expression of Oct-4. In stage IV, Oct-4 expression did not correlate with the 5-year survival rate. Furthermore, multivariate analysis suggested that the depth of invasion, lymph node metastasis, distant metastasis, TNM stage, and upregulation of Oct-4 were independent prognostic factors of gastric cancer.
Oct-4 protein is a useful marker in predicting tumor progression and prognosis.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S90031</identifier><identifier>PMID: 26869797</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Cancer therapies ; Care and treatment ; Chemotherapy ; Development and progression ; Gastric cancer ; Gastrointestinal surgery ; Gene expression ; Genetic aspects ; Health aspects ; Hospitals ; Liver cancer ; Lymphatic system ; Medical prognosis ; Metastasis ; Multivariate analysis ; Original Research ; Protein expression ; Proteins ; Stomach cancer ; Transcription factors ; Tumorigenesis ; Tumors</subject><ispartof>OncoTargets and therapy, 2016-01, Vol.9, p.517-522</ispartof><rights>COPYRIGHT 2016 Dove Medical Press Limited</rights><rights>2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Jiang et al. This work is published and licensed by Dove Medical Press Limited 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c602t-9ea92728744bf238ef5b32becc4d1beb56b8470dcac62dce7fe61b7d57662acc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734804/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734804/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26869797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jiang, Wen-Li</creatorcontrib><creatorcontrib>Zhang, Peng-Fei</creatorcontrib><creatorcontrib>Li, Guo-Feng</creatorcontrib><creatorcontrib>Dong, Jian-Hua</creatorcontrib><creatorcontrib>Wang, Xue-Song</creatorcontrib><creatorcontrib>Wang, Yuan-Yu</creatorcontrib><title>Oct-4 is associated with gastric cancer progression and prognosis</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>To investigate the clinical significance of Oct-4 in the development and progression of gastric cancer.
Immunohistochemistry was used to analyze Oct-4 expression in 412 gastric cancer cases. Oct-4 protein levels were upregulated in gastric cancer tissues compared with adjacent noncancerous tissues.
Positive expression of Oct-4 correlated with age, depth of invasion, Lauren classification, lymph node metastasis, distant metastasis, and TNM stage. In stages I, II, and III, the 5-year survival rate of patients with high expression of Oct-4 was significantly lower than that in patients with low expression of Oct-4. In stage IV, Oct-4 expression did not correlate with the 5-year survival rate. Furthermore, multivariate analysis suggested that the depth of invasion, lymph node metastasis, distant metastasis, TNM stage, and upregulation of Oct-4 were independent prognostic factors of gastric cancer.
Oct-4 protein is a useful marker in predicting tumor progression and prognosis.</description><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Gastric cancer</subject><subject>Gastrointestinal surgery</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Liver cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Original Research</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Stomach cancer</subject><subject>Transcription factors</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkl1rFDEUhoNYbK3e-ANkQBARZs3XJJkbYSlqC4W9cL0OmcyZ3ZTZZE0yiv_e1K3dXSlUcpGv57wn4X0RekXwjBIuPyyWy9nXFmNGnqAzQqSqRcvw04P1KXqe0g3GQijKn6FTKpRoZSvP0Hxhc80rlyqTUrDOZOirny6vq5VJOTpbWeMtxGobwypCSi74yvj-z96H5NILdDKYMcHLu_kcffv8aXlxWV8vvlxdzK9rKzDNdQumpZIqyXk3UKZgaDpGO7CW96SDrhGd4hL31lhBewtyAEE62TdSCGqsZefo4053O3UbKITP0Yx6G93GxF86GKePb7xb61X4oblkXGFeBN7dCcTwfYKU9cYlC-NoPIQpaSJFQ0ijeFPQN_-gN2GKvnxPU8ppK3DD1J5amRG080Mofe2tqJ43mBWsvP0RClOlWsIKNXuAKqOHjbPBw-DK-ZHsfxbsO7w9KFiDGfM6hXHKxdF0rPwIuFd8vwNtDClFGO7NIFjfJlOXZOpdMgv8-tC-e_RvFNlveKDaXA</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Jiang, Wen-Li</creator><creator>Zhang, Peng-Fei</creator><creator>Li, Guo-Feng</creator><creator>Dong, Jian-Hua</creator><creator>Wang, Xue-Song</creator><creator>Wang, Yuan-Yu</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Oct-4 is associated with gastric cancer progression and prognosis</title><author>Jiang, Wen-Li ; Zhang, Peng-Fei ; Li, Guo-Feng ; Dong, Jian-Hua ; Wang, Xue-Song ; Wang, Yuan-Yu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c602t-9ea92728744bf238ef5b32becc4d1beb56b8470dcac62dce7fe61b7d57662acc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Gastric cancer</topic><topic>Gastrointestinal surgery</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Liver cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Original Research</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Stomach cancer</topic><topic>Transcription factors</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Wen-Li</creatorcontrib><creatorcontrib>Zhang, Peng-Fei</creatorcontrib><creatorcontrib>Li, Guo-Feng</creatorcontrib><creatorcontrib>Dong, Jian-Hua</creatorcontrib><creatorcontrib>Wang, Xue-Song</creatorcontrib><creatorcontrib>Wang, Yuan-Yu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest_Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Wen-Li</au><au>Zhang, Peng-Fei</au><au>Li, Guo-Feng</au><au>Dong, Jian-Hua</au><au>Wang, Xue-Song</au><au>Wang, Yuan-Yu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oct-4 is associated with gastric cancer progression and prognosis</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>9</volume><spage>517</spage><epage>522</epage><pages>517-522</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>To investigate the clinical significance of Oct-4 in the development and progression of gastric cancer.
Immunohistochemistry was used to analyze Oct-4 expression in 412 gastric cancer cases. Oct-4 protein levels were upregulated in gastric cancer tissues compared with adjacent noncancerous tissues.
Positive expression of Oct-4 correlated with age, depth of invasion, Lauren classification, lymph node metastasis, distant metastasis, and TNM stage. In stages I, II, and III, the 5-year survival rate of patients with high expression of Oct-4 was significantly lower than that in patients with low expression of Oct-4. In stage IV, Oct-4 expression did not correlate with the 5-year survival rate. Furthermore, multivariate analysis suggested that the depth of invasion, lymph node metastasis, distant metastasis, TNM stage, and upregulation of Oct-4 were independent prognostic factors of gastric cancer.
Oct-4 protein is a useful marker in predicting tumor progression and prognosis.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>26869797</pmid><doi>10.2147/OTT.S90031</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2016-01, Vol.9, p.517-522 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4734804 |
| source | DOVE Medical Press Journals; PubMed Central Open Access; PubMed (Medline); Taylor & Francis; EZB Electronic Journals Library |
| subjects | Cancer therapies Care and treatment Chemotherapy Development and progression Gastric cancer Gastrointestinal surgery Gene expression Genetic aspects Health aspects Hospitals Liver cancer Lymphatic system Medical prognosis Metastasis Multivariate analysis Original Research Protein expression Proteins Stomach cancer Transcription factors Tumorigenesis Tumors |
| title | Oct-4 is associated with gastric cancer progression and prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A14%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oct-4%20is%20associated%20with%20gastric%20cancer%20progression%20and%20prognosis&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Jiang,%20Wen-Li&rft.date=2016-01-01&rft.volume=9&rft.spage=517&rft.epage=522&rft.pages=517-522&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S90031&rft_dat=%3Cgale_pubme%3EA500288913%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242960538&rft_id=info:pmid/26869797&rft_galeid=A500288913&rfr_iscdi=true |